Παρασκευή 15 Ιουλίου 2016

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Conditions:   Triple-Negative Breast Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Head and Neck Carcinoma, Squamous Cell;   Advanced Solid Tumors
Interventions:   Drug: TAK-659;   Drug: Nivolumab
Sponsor:   Millennium Pharmaceuticals, Inc.
Not yet recruiting - verified July 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/29VoQNh
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου